Premium
The effect of vigabatrin on brain and platelet GABA‐transaminase activities.
Author(s) -
Bolton JB,
Rimmer E,
Williams J,
Richens A
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb03459.x
Subject(s) - vigabatrin , gaba transaminase , pharmacology , platelet , anticonvulsant , drug , chemistry , medicine , enzyme , biochemistry , epilepsy , psychiatry , glutamate decarboxylase
1. The inhibition profiles of GABA‐transaminase (GABA‐T) in rat brain and platelet have been compared following a single intraperitoneal dose of vigabatrin. The inhibition profiles exhibit similarities. The inhibition produced by the drug is dose‐dependent and, in the dose range used in man, the dose‐response curves are comparable. The pharmaco‐dynamic effects of the drug (inhibition of central and peripheral GABA‐T) remain after the drug has been eliminated from plasma. It is suggested that the measurement of rat platelet GABA‐T may be used as a non‐invasive assessment of the efficacy of GABA‐T inhibitors in the rat CNS. 2. Human blood platelet GABA‐T was significantly inhibited by the administration of a single oral dose of vigabatrin. Chronic administration also produces a significant inhibition of platelet GABA‐T. As with rats, the pharmacodynamic effects on the platelet enzyme remained after the drug had been eliminated from plasma. If the situation in man is assumed to parallel that found in the rat then measurement of platelet GABA‐T inhibition could prove to be a useful indicator of central inhibition.